TheraRadar
Clinical-Stage Companies / Abivax

Abivax

Pre-Approval PRO BETA
23
Total Trials
6
Phase 3
15
Phase 2
5
Recruiting
236
Score

Pipeline by Phase

Phase 3
6
Phase 2
15
Phase 1
7

Therapeutic Focus

Ulcerative Colitis Healthy Volunteers Healthy Rheumatoid Arthritis COVID-19

Clinical Trials (23)

NCT05507216 Phase 3 COMPLETED

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Started: 12/21/2022

NCT05507203 Phase 3 COMPLETED

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Started: 10/10/2022

NCT05535946 Phase 3 ACTIVE NOT RECRUITING

ABTECT - Maintenance

Started: 1/16/2023

NCT06456593 Phase 2 RECRUITING

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Started: 10/30/2024

NCT03760003 Phase 2 COMPLETED

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Started: 8/13/2019

NCT04393038 Phase 2 TERMINATED

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Started: 7/1/2020

NCT04049448 Phase 2 COMPLETED

Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

Started: 10/25/2019

NCT05177835 Phase 2 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Started: 12/3/2021

NCT04023396 Phase 2 COMPLETED

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

Started: 1/13/2020

NCT03368118 Phase 2 COMPLETED

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

Started: 1/20/2018

NCT02735863 Phase 2 COMPLETED

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

Started: 5/1/2016

NCT03905109 Phase 2 WITHDRAWN

Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

Started: 9/19/2022

NCT03093259 Phase 2 COMPLETED

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Started: 11/16/2017

NCT03813199 Phase 2 COMPLETED

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

Started: 7/4/2019

NCT02249988 Phase 2 COMPLETED

Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B

Started: 12/1/2014

NCT02452242 Phase 2 COMPLETED

Safety, PK and PD Study of ABX464 in Untreated HIV Patients

Started: 1/1/2015

NCT07453784 Phase 1 RECRUITING

Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

Started: 3/3/2026

NCT03897543 Phase 1 RECRUITING

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Started: 8/30/2019

NCT02792686 Phase 1 COMPLETED

ABX464 First in Man Study

Started: 3/1/2014

NCT02990325 Phase 1 COMPLETED

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

Started: 3/27/2017

NCT05032560 Phase 1 COMPLETED

Safety and Pharmacokinetics Study in Healthy Japanese Volunteers

Started: 9/27/2021

NCT05121714 Phase 1 COMPLETED

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

Started: 12/17/2020

NCT02731885 Phase 1 COMPLETED

Food Effect on Pharmacokinetic Parameters of ABX464

Started: 9/1/2014

Drug Candidates

Obefazimod 50 mg Capsule Obefazimod Minitablet 50 mg ABX464 100 mg ABX464 50 mg ABX464 25 mg Placebo ABX464 Obefazimod Placebo oral capsule ABX464 150mg
Activity Status: Active
Last Trial Started: 3/3/2026
Last Trial Ended: 7/15/2025
Trials (12 months): 1
Completed Trials: 16
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.